J&J not ready to throw in the towel in body powder suits

body powder

Johnson & Johnson ($JNJ) may have lost two multimillion-dollar verdicts over its body powder products but don’t expect the company to throw in the towel just yet. With science on its side, you can bet the healthcare and consumer giant with continue to defend the popular product. 

Some experts think the losses might move J&J toward a global settlement. But Gene Williams, a Houston-based attorney who has defended the company during three powder lawsuits disagrees. He tells Reuters the company will continue to argue in court that its talc-based J&J Baby Powder and Shower to Shower are safe. Plaintiffs have claimed that the products cause ovarian cancer.

There “is no proven linkage between talc and ovarian cancer, and the vast majority of scientific and regulatory bodies, who have reviewed the same studies the plaintiffs point to, do not accept the premise,” Williams said. “The science supporting the safety of talc has gotten stronger and stronger.”

Conference

The 13th Annual Digital Pharma East

Digital Pharma East returns to the Pennsylvania Convention Center September 17–20, bringing together over 1000 attendees from biotech and pharma, to better understand how to present business plans, justify budget and innovation, and de-risk proposals getting shut down — essentially, understand how they can return to the office and become champions for their internal digital needs. Join us and save 15% on standard rates when you register with Discount Code DPE19Fierce.

J&J will need to make that argument--and make it well--when it faces two body powder lawsuits this fall scheduled for trial in Missouri and New Jersey. At least 1,400 cases have been filed over related claims, Reuters reports, and most of those are in Missouri where rules tend to favor plaintiffs.

The company has already suffered some stinging courtroom defeats over its body powder products. In February, a Missouri state jury slapped J&J with a $72 million verdict in a case alleging that the company downplayed risks associated with its body powder in order to boost sales.

In May, the company lost its second jury trial over cancer risks tied to its body powders. A jury in the same St. Louis, MO-based court awarded $55 million to plaintiff Gloria Ristesund, who claimed that she developed ovarian cancer after using J&J’s products for feminine hygiene. In an earlier trial in South Dakota, a jury said J&J had been negligent but did not award any damages and there was not appeal.

J&J has said that it would continue to defend its position in court but some legal experts thought that two unfavorable verdicts might push the company toward a settlement.

“The more talc verdicts that come down against them adds to the public’s growing distrust of their baby powder, which is one of their iconic products,” University of Richmond law professor Carl Tobias said earlier this month. “There are both economic and reputational issues that may motivate them to start thinking about a global settlement of these cases.”

- read the Reuters story

Related Articles:
Jury slaps J&J with $55M in damages in talcum-powder cancer case
J&J hit with $72M verdict in body powder case alleging cancer risk

Read more on

Suggested Articles

Leading Indian drugmakers Sun Pharma, Cipla, Aurobindo and Dr. Reddy's are all trying to expand their presences in China.

New Gilead CEO Daniel O’Day has already replaced some key leaders at the company, but he’s not stopping there with the executive overhaul.

The FDA lambasted Strides Pharma in a warning letter after inspectors found testing records in the trash and in bags by a shredder.